5-HT4 Partial Agonist | RaQualia Pharma Inc.

Compound Code	RQ-00000009
Primary Target Indications	Alzheimer's disease
Development Stage	Phase 1 Portfolio for global development, manufacturing, and marketing rights
Product Summary	It is believed that the 5-HT₄ receptor agonist can contribute to Alheimer's disease treatment by promoting the release of acetylcholine from nerve cells and by controlling the metabolism of amyloid precursor peptides. RQ-9 is a 5-HT₄ receptor partial agonist, which is potent, highly selective and can penetrate the central nervous system. In Phase 1, we have confirmed its tolerability, safety and pharmacokinetics.
Non-Confidential Materials	5-HT₄ Alzheimer's disease (159KB)

Compound Code	RQ-00000010
Primary Target Indications	Gastro-esophageal reflux disease
Development Stage	Pre-clinical trials Portfolio for global development, manufacturing, and marketing rights
Product Summary	RQ-10 is a potent 5-HT₄ partial agonist, and it has the potential to be an innovative drug for GERD treatment that eliminates heart/vascular risks. In animal models it has exhibited a strong effect.
Non-Confidential Materials	5-HT₄ GERD (158KB)